World Health Organization’s INN Approves “Desmetramadol” as Generic Name for Omnitram

World Health Organization’s INN Approves “Desmetramadol” as Generic Name for Omnitram
March 29, 2018 Syntrix

Syntrix today announced that the World Health Organization’s International Nonproprietary Name (INN) group have accepted the proposed generic name “Desmetramadol” for its pain drug racemic O-desmethyltramadol (working name of Omnitram).

John Zebala, M.D., Ph.D., CEO of Syntrix, said that “Desmetramadol is poised to enter Phase 3 and assignment of a unique generic name is an important step forward to ultimate marketing authorization.”

The United States Adopted Names (USAN) Council, part of the American Medical Association (AMA), is responsible for selecting simple, informative and unique nonproprietary (generic) drug names. The World Health Organization’s International Nonproprietary Names (INN) facilitates the identification of pharmaceutical substances or active pharmaceutical ingredients. Each INN is a unique name that is globally recognized and is public property.

ABOUT DESMETRAMADOL (Working name Omnitram): While there are 25 million patients sufferng from daily pain in America, there was an estimated 20,500 prescription opioid deaths due to overdose with the dangerous Schedule II opioids.  Treating pain safely remains a difficult clinical problem and unmet need.  Desmetramadol is a new investigational pain medication being developed as the first safer Schedule IV opioid without metabolic liabilities and related “black box” safety warnings of other opioids like codeine and tramadol.  Many of the 170 million Schedule II prescriptions in the U.S. could potentially be replaced with an effective, but safer Schedule IV analgesic like desmetramadol.

ABOUT SYNTRIX: Syntrix is a pharmaceutical company committed to discovering and delivering innovative therapies by doing things differently.  We innovate in discovery and clinical trials, engineer risk prospectively, integrate IP strategy creatively, and leverage non-dilutive capital to solve the most difficult clinical problems. Convergent Science & Strategy. Breakthrough Medicines.

DISCLOSURE NOTICE: This release contains forward-looking information that are based on company management’s current beliefs and expectations and are subject to currently unknown information, risks and circumstances and actual results may vary from what is being currently projected.  In addition, from time to time, Syntrix or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should”, “could” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Syntrix’s actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause Syntrix’s actual activities or results to differ materially from the activities and results anticipated in such forward-looking statements.  Syntrix does not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contact: Aaron Schuler, PhD, 253-833-8009, x21


Leave a reply

Your email address will not be published. Required fields are marked *